Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same author

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

Expert opinion on pharmacotherapy·2026
Same author

Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.

Kidney international reports·2026
Same author

Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseases.

Clinical kidney journal·2026
Same author

Mineral, Bone, and Cardiovascular Disorders in CKD: The Case for a New Paradigm.

Kidney medicine·2026
Same author

Hemoadsorption Combined with Hemodialysis (HAHD): a Consensus Statement from an International Expert Panel.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Related Experiment Video

Updated: Jun 4, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Calciphylaxis: a still unmet challenge.

Vincent M Brandenburg1, Mario Cozzolino, Markus Ketteler

  • 1Department of Cardiology, University Hospital Aachen, Aachen, Germany. Vincent.Brandenburg@post.rwth-aachen.de

Journal of Nephrology
|February 22, 2011
PubMed
Summary
This summary is machine-generated.

Calcific uremic arteriolopathy (CUA), or calciphylaxis, is a painful, life-threatening condition in advanced kidney disease patients. Current treatments aim to manage symptoms and risk factors, but further research is needed to improve outcomes and reduce mortality.

Related Experiment Videos

Last Updated: Jun 4, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Area of Science:

  • Nephrology
  • Dermatology
  • Vascular Biology

Background:

  • Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare and severe condition primarily affecting patients with end-stage renal disease.
  • Characterized by painful skin lesions and ulcerations, CUA results from calcification and occlusion of small cutaneous arterioles.
  • The disease carries a high mortality risk due to associated infections and cardiovascular complications.

Purpose of the Study:

  • To review the current understanding of calcific uremic arteriolopathy, encompassing its pathophysiology, clinical presentation, disease progression, and therapeutic strategies.
  • To synthesize existing literature data with personal clinical experiences to provide a comprehensive overview.

Main Methods:

  • Conducted a literature search using terms 'calciphylaxis' and 'calcific uremic arteriolopathy'.
  • Summarized current knowledge on the disease's pathophysiology, clinical features, course, and treatment options.
  • Integrated personal treatment experiences with findings from the literature review.

Main Results:

  • CUA development is linked to a complex interplay of local and systemic risk factors, with incomplete understanding of the underlying pathophysiology.
  • Patients with advanced chronic kidney disease (CKD) and those on dialysis are particularly susceptible.
  • Therapeutic approaches include optimizing dialysis, managing CKD-mineral and bone disorder, experimental anticalcification treatments, and wound care, though evidence is primarily from case reports and series.

Conclusions:

  • Despite current interventions, calciphylaxis continues to have a poor prognosis, highlighting the urgent need for further research into prophylaxis and treatment.
  • Existing treatment strategies may offer some benefit in disease management but their impact on overall mortality remains uncertain.